引进授权和对外授权决策是制药公司管理其产品组合以实现增长和平衡的重要渠道。引进授权决策通常是为了扩大或巩固公司在某一治疗领域的地位；而对外授权决策则更多地源于与新产品开发投资和市场准入因素相关的风险和价值权衡，或者是为了提升“尾部”成熟在线产品的性能。
We support our larger clients by conducting due diligence on in-licensing assets and establishing deal negotiation ranges by identifying “tipping off” and “walkaway” points. We also support emerging innovator companies in out-licensing their assets outright or in developing partnering arrangements with larger companies. Often our support extends to negotiating deal terms and facilitating our clients to take partnering decisions. For mature portfolios with extensive “tails”, we help our clients develop win/win arrangements with partners to out-license or develop profit-sharing arrangements with partners.
We work with clients on these decisions at all stages of asset development and also in-line products.